Abstract
In this study, we investigated the efficacy and safety of administration of Linezolid (LZD) to pediatric febrile neutropenia (FN) patients after cancer chemotherapy. The study period was from January 2008 to June 2014, and the subjects were patients under the age of 16 receiving LZD administration (9 subjects, 16 cases, average age 9.2 ± 4.4 years). The dose of LZD was 30.7 ± 3.1 mg/kg/day, and the administration period was 12.1 ± 6.3 days. The test values were as follows: the CRP decreased from 3.9 ± 4.5 mg/dL to 0.4 ± 0.7 mg/dL (P < 0.01), the PLT increased from 7.1 ± 4.69 × 104 /μL to 14.5 ± 9.1 × 104 /μL (P < 0.01) and the WBC increased from 9.4 ± 21.6 × 102 /μL to 42.2 ± 38.5 × 102 /μL (P < 0.01); thus, statistically significant differences were obtained. The reason for the termination of LZD administration was due to the alleviation of the symptoms, which was observed in 14 cases (14/16 87.5%). Survival after 30 days was confirmed in all of the cases. The results suggest that LZD administration to FN pediatric patients is effective and safe.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
